Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.

Segment	Revenue
Services	177.81M
Foundry Revenue	112.99M
Product	23.04M

NYSE:DNA

Ginkgo Bioworks Holdings, Inc.

$

Last Close

1.77

25/09 20:00

Market Cap

3.63B

Beta: -

Volume Today

11.63M

Avg: 23.29M

PE Ratio

-0.99

PEG: -

industry

exchange

website

ipo date

full time employees

currency

Earnings

Earnings per Share (Estimate)

Revenue (Estimate)

Revenue Breakdown

Related Tickers

Metrics

Please Sign In To Use The Chat